Leukemia, Myeloid: all 2,432 studies

Page 24 of 25. Open to participants first (205), then studies with results posted, then the rest; newest registration first within each.

• Study of Tipifarnib as Postconsolidation Therapy for Acute Myeloid Leukemia in Patients 60 Years and OlderCompletedNCT00048503Phase 2
• Anti-Leukemic Dendritic Cell Activated Donor LymphocytesTerminatedNCT00048100Phase 1
• Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedNCT00047502Phase 1
• Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00045422Phase 2
• A Phase II Study Of The Farnesyltransferase Inhibitor ZANESTRA (R115777, NSC #702818, IND #58,359) In Complete Remission Following Induction And/Or Consolidation Chemotherapy In Adults With Poor-Risk Acute Myelogenous Leukemia (AML) And High-Risk Myelodysplasia (MDS)CompletedNCT00045396Phase 2
• Phase II Study of Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous LeukemiaCompletedNCT00044889Phase 2
• Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell TransplantCompletedNCT00044733Phase 2
• Prophylaxis Trial of Posaconazole Versus Standard Azole Therapy for Neutropenic Patients (Study P01899)CompletedNCT00044486Phase 3
• Study of Gelonin Purging of Autologous Stem Cells for TransplantationTerminatedNCT00043810Phase 1/2
• Decitabine in Treating Children With Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaTerminatedNCT00042796Phase 1
• Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) PatientsCompletedNCT00042354Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042016Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00042003Phase 2
• Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Accelerated Phase Who Are Refractory to Imatinib Mesylate (Gleevec)CompletedNCT00041990Phase 2
• Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00040105Phase 1
• Oblimersen, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00039117Phase 1
• Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung CancerTerminatedNCT00039091Phase 1
• Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated LymphocytesWithdrawnNCT00038870Not applicable
• Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDSCompletedNCT00038831Phase 1/2
• CD8 DLI for Patients With Relapse or Residual Disease Following Allogeneic Stem Cell TransplantationTerminatedNCT00038818Not applicable
• Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedNCT00038597Phase 2
• PEG-Intron For Chronic Myelogenous Leukemia Patients Unresponsive To Or Intolerant Of Roferon Or IntronTerminatedNCT00037882Phase 2
• Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid LeukemiaCompletedNCT00037596Phase 2
• Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid LeukemiaCompletedNCT00037583Phase 2
• Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)CompletedNCT00034684Phase 1/2
• Imatinib Mesylate in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030394Phase 2
• Vaccine Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00030303Phase 1
• Open Study of CEP-701 in Patients With Refractory Acute Myeloid Leukemia With FLT-3 MutationCompletedNCT00030186Phase 2
• Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromesCompletedNCT00028899Phase 1
• Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00027924Phase 2
• Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid LeukemiaCompletedNCT00027872Phase 2
• Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00027820Phase 1/2
• Study Using Vaccination With Heat Shock Protein 70 (HSP70) for the Treatment of CML in Chronic PhaseCompletedNCT00027144Phase 1
• Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver DysfunctionCompletedNCT00025415Phase 1
• Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous LeukemiaStatus unknownNCT00025402Phase 3
• Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous LeukemiaTerminatedNCT00023920Phase 2
• Bortezomib in Treating Patients With Chronic Myelogenous LeukemiaTerminatedNCT00023881Phase 2
• S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00023777Phase 2
• Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid LeukemiaCompletedNCT00017589Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid LeukemiaCompletedNCT00017472Phase 1
• Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute LeukemiaCompletedNCT00016016Phase 1/2
• STI571 Plus Combination Chemotherapy in Treating Patients With Chronic Myelogenous Leukemia or Acute Lymphocytic LeukemiaCompletedNCT00015860Phase 1/2
• STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00015834Phase 1/2
• Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic MalignanciesCompletedNCT00014235Not applicable
• Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid CancerCompletedNCT00012376Phase 1
• Troxacitabine in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00012259Phase 2
• Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00008151Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast CrisisCompletedNCT00006475Phase 2
• Gemcitabine in Treating Children With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelogenous LeukemiaCompletedNCT00006462Phase 2
• Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00006364Phase 2
• Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006363Phase 3
• STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT00006343Phase 3
• Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid LeukemiaCompletedNCT00006265Phase 2
• Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic CancerCompletedNCT00006251Phase 1/2
• Phenylbutyrate, Dexamethasone, and Sargramostim in Treating Patients With Refractory or Relapsed Acute Myeloid LeukemiaCompletedNCT00006240Phase 2
• flt3L in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00006223Phase 3
• BMS-214662 in Treating Patients With Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myeloid LeukemiaCompletedNCT00006213Phase 1
• Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00006122Phase 2
• Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous TreatmentWithdrawnNCT00006091Phase 2
• Monoclonal Antibody in Treating Patients With Acute Myelogenous LeukemiaStatus unknownNCT00006084Phase 2
• STI571 in Treating Patients With Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaCompletedNCT00006053Phase 2
• STI571 in Treating Patients With Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT00006052Phase 2
• Chemotherapy, Filgrastim and Peripheral Stem Cell Transplantation in Patients With Chronic Myelogenous LeukemiaTerminatedNCT00005986Phase 2
• Cyclophosphamide and Filgrastim Followed By SCT in Patients With Chronic or Accelerated Phase Myelogenous LeukemiaTerminatedNCT00005984Phase 2
• Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous LeukemiaCompletedNCT00005962Phase 2
• Chemotherapy Followed by Peripheral Stem Cell Transplantation And Biological Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00005948Phase 2
• Radiolabeled BC8 Antibody, Busulfan, Cyclophosphamide Followed by Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia in First RemissionCompletedNCT00005940Phase 2
• S9920 Busulfan Compared With Cyclophosphamide in Patients Undergoing Total-Body Irradiation Plus Peripheral Stem Cell Transplantation for Advanced Myelodysplastic Syndrome or Related Acute Myeloid LeukemiaCompletedNCT00005866Phase 3
• Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00005823Phase 3
• Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancerCompletedNCT00005799Not applicable
• Arsenic Trioxide in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00005795Phase 2
• Arsenic Trioxide in Treating Patients With Relapsed or Refractory Chronic Myelogenous LeukemiaCompletedNCT00005618Phase 2
• PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic SyndromeCompletedNCT00005064Phase 1
• Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon AlfaTerminatedNCT00004933Phase 3
• Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic SyndromeCompletedNCT00004918Phase 1/2
• Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute LeukemiaCompletedNCT00004905Phase 2
• Chemotherapy Plus Bone Marrow Transplantation and Filgrastim in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004899Phase 2
• Busulfan and Cyclophosphamide Followed by Bone Marrow Transplantation in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004896Phase 2
• Azacitidine Plus Phenylbutyrate in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeCompletedNCT00004871Phase 1
• Augmerosen Plus Fludarabine and Cytarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaCompletedNCT00004862Phase 1
• Cytarabine and UCN-01 in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00004263Phase 1
• Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaCompletedNCT00004245Phase 1
• S9918 PSC 833, Daunorubicin, and Cytarabine in Treating Older Patients With Newly Diagnosed Acute Myeloid LeukemiaCompletedNCT00004217Phase 2
• Leridistim Compared With Filgrastim in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00004215Phase 2
• Bone Marrow Transplantation in Treating Patients With Multiple Myeloma, Chronic Phase Chronic Myelogenous Leukemia, or Agnogenic Myeloid MetaplasiaCompletedNCT00004181Phase 2
• Vaccine Therapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00004052Phase 2
• R115777 in Treating Patients With Refractory or Recurrent Acute Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00004009Phase 1
• 6-Hydroxymethylacylfulvene in Treating Patients With Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Blastic Phase Chronic Myelogenous LeukemiaCompletedNCT00003997Phase 1
• Interleukin-2 Plus Histamine Dihydrochloride in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00003991Phase 3
• Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic LeukemiaCompletedNCT00003934Phase 3
• Diagnostic Study of Gene Alterations in Patients With Acute Myeloid LeukemiaCompletedNCT00003931
• Radiolabeled Monoclonal Antibody, Cyclophosphamide, and Total Body Irradiation Followed By Donor Stem Cell Transplantation in Treating Patients With Advanced Acute Myeloid LeukemiaCompletedNCT00003868Phase 2
• DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid LeukemiaCompletedNCT00003840Phase 1/2
• Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous LeukemiaStatus unknownNCT00003758Phase 2
• Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous LeukemiaCompletedNCT00003727Phase 2
• Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic PhaseCompletedNCT00003694Phase 2
• Dolastatin 10 in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous LeukemiaCompletedNCT00003693Phase 1
• CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First RelapseCompletedNCT00003673Phase 2
• Combination Chemotherapy in Treating Older Patients With Acute Myeloid LeukemiaStatus unknownNCT00003602Phase 3
• Interferon Alfa Plus Sargramostim in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaTerminatedNCT00003561Phase 2

← Leukemia, Myeloid overview